Sachs Associates’ Post

View organization page for Sachs Associates, graphic

2,849 followers

Nouscom is a private clinical stage immuno-oncology company developing next-generation, off-the-shelf and personalized cancer immunotherapies. Our proprietary viral vector platform has the capacity to encode for large payloads of neoantigens or other immunomodulators and is clinically demonstrated to safely and potently harness the power of the immune system. The company recently closed an oversubscribed Series 'C' financing, to advance the clinical development of its wholly owned programs. These programs include NOUS-209, an off-the-shelf cancer immunotherapy for the treatment of MSI-H solid tumors in combination with pembrolizumab in randomized phase 2 trials, with readouts expected in 2025. In January 2023, Nouscom announced a clinical trial collaboration and pembrolizumab supply agreement with MSD (Merck & Co). A Phase 1b study of NOUS-209 monotherapy in Lynch Syndrome Carriers with potential to ‘intercept cancer’ before it occurs is running with the National Cancer Institute, with the first interim data reported at SITC Conference in November 2023. A randomized pivotal trial in Lynch Syndrome is expected to be initiated in 2025. Nouscom's second clinical program is NOUS-PEV, a personalized cancer immunotherapy for the treatment of advanced melanoma and lung cancer that will be entering randomized Phase 2 trials in 2025. Nouscom has also exclusively out-licensed VAC-85135, an off-the-shelf immunotherapy developed under a multi-project agreement, which is currently under evaluation in a Phase 1 trial for the treatment of Myeloproliferative Neoplasms sponsored by Janssen Research & Development and Bristol-Myers Squibb Meet Nouscom AG @ #Sachs_BEF More Info @ https://lnkd.in/d7zEuKym #BigPharma #Dealmakers #PharmaIndustry #BiotechInEuropeForum #LifeSciences #Biotech #BioPharma #Partnering #Investment #Startups #Oncology #Neurology #Genomics #Immunotherapy #CNS #Autoimmune #Cardiovascular #BiotechIndustry #BioTechInvestment #Innovation #InvestmentForum #BiotechConference #EuropeanBiotech #SachsAutumnLifeSciencesWeek #SALSW

  • No alternative text description for this image

To view or add a comment, sign in

Explore topics